You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In PLOS this week: investigation of pleiotropic effects using GWAS data, transcriptomic study of mosquitoes that spread Rift Valley fever, and more.
An advisory panel to the US Food and Drug Administration voted for authorizing Pfizer and BioNTech's SARS-CoV-2 vaccine, the Wall Street Journal reports.
Early trial data of a Sanofi and GlaxoSmithKline SARS-CoV-2 vaccine indicates an insufficient immune response among older participants, according to Reuters.
Science reports that Tasmanian devils are passing devil facial tumor disease on to a smaller number of other devils.
In Science this week: CRISPR and expression-reported sequencing approach to trace genetic interactions, sample preparation platform for single-cell sequencing, and more.
Australian researchers say a nanopore sequencing strategy could quickly trace the source of a SARS-CoV-2 infection, according to Reuters.
The Chronicle of Higher Education reports that faculty are concerned that pandemic-induced budget cuts will affect the university ecosystem.
A gene therapy for Leber hereditary optic neuropathy given to one eye affected vision of the other, according to New Scientist.
In Nature this week: donkey genome gives insight into domestication, workflow for reference-free assembly of fully phased diploid human genomes, and more.
BuzzFeed News reports that published results from AstraZeneca and Oxford University about their vaccine don't clear up all questions.
The United Arab Emirates has announced that a SARS-CoV-2 vaccine developed by China's Sinopharm has high efficacy, according to the Financial Times.
The Guardian reports the UK is planning a clinical trial that will 'mix and match' vaccines.
In Genome Biology this week: relapse-linked mutations in T cell acute lymphoblastic leukemia, single-cell atlas of human tissue transcriptomes, and more.
FDA document indicates the Pfizer/BioNTech SARS-CoV-2 vaccine meets the expectations the agency has for an EUA, according to Reuters.
According to the Guardian, researchers have uncovered a set of proteins that might be able to predict whether COVID-19 patients will need intensive care.
The Washington Post reports on efforts to study human stem cells in microgravity.
In PNAS this week: Andean and Amazonian population genetics, lipid metabolism changes in gastric cancer linked to ferroptosis avoidance, and more.
According to the New York Times, President-elect Joe Biden is nominating Xavier Becerra to lead the Department of Health and Human Services.
Researchers report promising results from a study examining a CRISPR-based treatment for sickle-cell disease, according to the Associated Press.
The Washington Post reports officials expect fewer SARS-CoV-2 vaccine doses to be available by the end of the year than was predicted earlier in the pandemic.
In PLOS this week: integrative software tool to analyze microbiome data, lipidome of ascariasis-causing nematode, and more.
IBM security researchers warn of a phishing campaign targeted at organizations involved in the distribution of SARS-CoV-2 vaccines, the Verge reports.
A researcher accused of smuggling research materials out of the US has pleaded guilty to making false statements, according to the Associated Press.
The Illinois police have cut the number of DNA tests waiting to be run in about half, CBS Chicago reports.
In Science this week: gene expression signature linked to nonalcoholic fatty liver disease progression, and more.
New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.
According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.
The US National Institutes of Health has a new initiative to address structural racism in biomedical research.
In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.